WooGene B&G Co. Ltd (018620) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.015x

Based on the latest financial reports, WooGene B&G Co. Ltd (018620) has a cash flow conversion efficiency ratio of 0.015x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩987.57 Million ≈ $669.26K USD) by net assets (₩66.90 Billion ≈ $45.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See WooGene B&G Co. Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

WooGene B&G Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how WooGene B&G Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

WooGene B&G Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of WooGene B&G Co. Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Woongjin Thinkbig Co Ltd
KO:095720
0.019x
Rapala VMC Oyj
HE:RAP1V
0.083x
Advance Synergy Bhd
KLSE:1481
0.065x
Mind Technology Inc
NASDAQ:MIND
0.022x
Sino Tactful Co Ltd
TWO:5481
-0.014x
Spectral AI Inc.
NASDAQ:MDAI
0.305x
Innometry Co. Ltd
KQ:302430
0.019x
IBKS No2 SPAC
KQ:204840
-0.088x

Annual Cash Flow Conversion Efficiency for WooGene B&G Co. Ltd (2011–2024)

The table below shows the annual cash flow conversion efficiency of WooGene B&G Co. Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see WooGene B&G Co. Ltd market cap and net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩27.79 Billion
≈ $18.83 Million
₩6.78 Billion
≈ $4.60 Million
0.244x +540.75%
2023-12-31 ₩72.33 Billion
≈ $49.02 Million
₩2.76 Billion
≈ $1.87 Million
0.038x -47.68%
2022-12-31 ₩35.32 Billion
≈ $23.93 Million
₩2.57 Billion
≈ $1.74 Million
0.073x -44.60%
2021-12-31 ₩31.14 Billion
≈ $21.11 Million
₩4.09 Billion
≈ $2.77 Million
0.131x +58.90%
2020-12-31 ₩29.85 Billion
≈ $20.23 Million
₩2.47 Billion
≈ $1.67 Million
0.083x +221.95%
2019-12-31 ₩27.27 Billion
≈ $18.48 Million
₩-1.85 Billion
≈ $-1.25 Million
-0.068x +51.68%
2018-12-31 ₩26.51 Billion
≈ $17.97 Million
₩-3.72 Billion
≈ $-2.52 Million
-0.140x -110.00%
2017-12-31 ₩23.04 Billion
≈ $15.61 Million
₩-1.54 Billion
≈ $-1.04 Million
-0.067x -151.96%
2016-12-31 ₩22.14 Billion
≈ $15.00 Million
₩2.85 Billion
≈ $1.93 Million
0.129x +279.51%
2015-12-31 ₩21.90 Billion
≈ $14.84 Million
₩-1.57 Billion
≈ $-1.06 Million
-0.072x -199.97%
2014-12-31 ₩20.67 Billion
≈ $14.01 Million
₩1.48 Billion
≈ $1.00 Million
0.072x -36.08%
2012-12-31 ₩18.56 Billion
≈ $12.58 Million
₩2.08 Billion
≈ $1.41 Million
0.112x +157.29%
2011-12-31 ₩17.74 Billion
≈ $12.02 Million
₩773.08 Million
≈ $523.90K
0.044x --

About WooGene B&G Co. Ltd

KQ:018620 Korea Pharmaceuticals
Market Cap
$47.60 Million
₩70.24 Billion KRW
Market Cap Rank
#22159 Global
#1365 in Korea
Share Price
₩2705.00
Change (1 day)
+4.44%
52-Week Range
₩670.00 - ₩3400.00
All Time High
₩6913.04
About

WooGene B&G Co., Ltd. develops, manufactures, and markets products to animal health and livestock industry in South Korea and internationally. The company's products include veterinary medicines, raw materials, and probiotic. It offers veterinary medicines for poultry, swine, bovine, horse, dog, cat, sheep, deer, and aquaculture markets; and vaccines for swine, poultry, canine, and cow markets. T… Read more